Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial T...

by Josep M Llibre, François Raffi, Graeme Moyle, Georg Behrens, Stephane Bouee, Geraldine Reilly, Peter Borg, David Piontkowsky, Felipe Rogatto
Published 2016-01-01

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.

by Josep M Llibre, François Raffi, Graeme Moyle, Georg Behrens, Stephane Bouee, Geraldine Reilly, Peter Borg, David Piontkowsky, Felipe Rogatto
Published 2016-01-01

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 cl...

by Yeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, Amanda Clarke, Khuanchai Supparatpinyo, Anchalee Avihingsanon, Winai Ratanasuwan, Sasisopin Kiertiburanakul, Kiat Ruxrungtham, SangYoun Yang, Susan Guo, YaPei Liu, Moupali Das, Do Tran, Damian McColl, Roberto Corales, Chris Nguyen, David Piontkowsky
Published 2019-05-01

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.

by Gregory D Huhn, Moti Ramgopal, Mamta K Jain, Federico Hinestrosa, David M Asmuth, Jihad Slim, Deborah Goldstein, Shauna Applin, Julie H Ryu, Shuping Jiang, Stephanie Cox, Moupali Das, Thai Nguyen-Cleary, David Piontkowsky, Bill Guyer, Lorenzo Rossaro, Richard H Haubrich
Published 2020-01-01